How Recurrent Strep A Infections Affect the Brain

Newly discovered route by which immune cells reach the brain may underlie an autoimmune neuropsychiatric disorder in children

NEW YORK, NY (December 14, 2015)—Researchers have discovered how immune cells triggered by recurrent Strep A infections enter the brain, causing inflammation that may lead to autoimmune neuropsychiatric disorders in children. The study, performed in mice, found that immune cells reach the brain by traveling along odor-sensing neurons that emerge from the nasal cavity, not by breaching the blood-brain barrier directly. The findings could lead to improved methods for diagnosing, monitoring, and treating these disorders.

The study, led by researchers at Columbia University Medical Center (CUMC) and the University of Minnesota, Minneapolis, was published today in the online edition of the Journal of Clinical Investigation.

Recurrent Group A streptococcus (S. pyogenes) infections, which cause “strep throat,” have been linked to autoimmune neuropsychiatric disorders, notably Pediatric Autoimmune Neuropsychiatric Disorders associated with Streptococcal infections, or PANDAS. Children with PANDAS exhibit Tourette’s syndrome–like motor and vocal tics or obsessive-compulsive behaviors that appear to happen “out of the blue.”

The Strep A bacterial cell wall contains molecules similar to those found in human heart, kidney, or brain tissue, according to a co-leader of the study, Dritan Agalliu, PhD, assistant professor of pathology and cell biology (in neurology and pharmacology) at Columbia University Medical Center. These “mimetic” molecules are recognized by the immune system, which responds by producing protective antibodies. But because of this molecular mimicry, the antibodies react not only to the bacteria but also to the host tissues, producing autoantibodies that attack the body’s own tissues. Previously, scientists did not understand how these autoantibodies would gain access to the brain, because brain vessels form an extremely tight blood-brain barrier that prevents free movement of molecules, antibodies and immune cells from the blood into the brain.

A few years ago, researchers discovered that recurrent Strep A infections trigger the production of immune cells known as Th17 cells, a type of helper T cell, in the nasal cavity. But it was unclear how these Th17 cells lead to brain inflammation and symptoms such as those seen in children with PANDAS.

Studying the tissues of mice infected intranasally with Strep A, Drs. Agalliu and colleagues found that bacterial-specific Th17 cells move along the surface of olfactory, or odor-sensing, axons that extend from the nasal cavity through the cribriform plate, a sieve-like bone that separates the nasal cavity from the brain. From there, the cells reach the olfactory bulb in the brain, which processes information about odors.

“Once the Th17 cells enter the brain, they break down the blood-brain barrier, allowing autoantibodies and other Th17 cells to enter the brain and promote neuroinflammation,” said Dr. Agalliu. “What’s interesting is that we see abundant Group A Strep bacteria in the nose, but they never penetrate the brain,” he added. “This is different from Group B Strep—the cause of bacterial meningitis—which causes neuroinflammation by entering the brain directly.”

The findings may lead to a more definitive diagnostic test for PANDAS, which is currently diagnosed based on clinical symptoms and the presence of Strep A infection or autoantibodies against brain proteins. “We are also interested in exploring ways to treat the disorder by repairing the blood-brain barrier itself to prevent the entry of autoantibodies into the brain,” said Dr. Agalliu.


The study’s other co-leader was P. Patrick Cleary, PhD, emeritus professor of microbiology at the University of Minnesota, Minneapolis.

The study is titled, “Group A Streptococcus intranasal infection promotes CNS infiltration by streptococcal-specific Th17 cells.” The other contributors are: Thamotharampillai Dileepan (University of Minnesota, Minneapolis), Erica D. Smith (University of California, Irvine), Daniel Knowland (University of California, Irvine), Martin Hsu (University of California, Irvine), Maryann Platt (CUMC), Peter Bittner-Eddy (University of Minnesota), Brenda Cohen (University of Minnesota), Peter Southern (University of Minnesota), Elizabeth Latimer (Georgetown University, Washington, DC), and Earl Harley (Georgetown).

The study was supported in part by grants from the National Health Lung, and Blood Institute (7R01 633 HL116995-01), the National Multiple Sclerosis Society, and a generous donation from Newport Equities LLC.

The researchers declare no financial or other conflicts of interest.

Columbia University Medical Center provides international leadership in basic, preclinical, and clinical research; medical and health sciences education; and patient care. The medical center trains future leaders and includes the dedicated work of many physicians, scientists, public health professionals, dentists, and nurses at the College of Physicians and Surgeons, the Mailman School of Public Health, the College of Dental Medicine, the School of Nursing, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. Columbia University Medical Center is home to the largest medical research enterprise in New York City and State and one of the largest faculty medical practices in the Northeast. For more information, visit or